2. Academic Validation
  3. Citrus polymethoxyflavones degrade estrogen receptor-alpha (ERα) and combine with tamoxifen for the treatment of estrogen receptor-positive breast cancer

Citrus polymethoxyflavones degrade estrogen receptor-alpha (ERα) and combine with tamoxifen for the treatment of estrogen receptor-positive breast cancer

  • Heliyon. 2024 Jun 14;10(12):e33104. doi: 10.1016/j.heliyon.2024.e33104.
Yiyu Wang 1 2,  Meng Sun 1,  Zhong He 1 2,  Ying Han 1,  Yinhong Song 2,  Jianjia Liang 1,  Huimin Wang 1,  Ye Qin 3,  Zhangshuang Deng 1
Affiliations

Affiliations

  • 1 Hubei Key Laboratory of Natural Products Research and Development, College of Biological and Pharmaceutical Sciences, China Three Gorges University, Yichang 443002, China.
  • 2 Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, College of Basic Medical Science, China Three Gorges University, Yichang 443002, China.
  • 3 State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
PMID: 39022050 DOI: 10.1016/j.heliyon.2024.e33104
Abstract

Estrogen receptor-positive (ER+) breast Cancer seriously endangers the women's physical and mental health worldwide and ER targeting therapy is vital. Here, we found that a citrus polymethoxyflavones (PMFs)-rich hydrolysate (C-H) and its major components (nobiletin and 3-methoxynobiletin) potently degrade ERα protein via the ubiquitin-proteasome pathway, thereby impairing the proliferation of ER+ breast Cancer cells. Moreover, our study exhibited that C-H combined with tamoxifen (TAM) inhibited the cell proliferation of ER+ breast Cancer in vitro. It was further confirmed that C-H decreased tumor growth of ER+ breast Cancer in tumor-bearing 129 mice in vivo and improved the efficacy of tamoxifen. Our study revealed that the citrus PMFs have potential applications as pharmaceutical and healthcare products in breast Cancer treatment by targeting ERα protein degradation.

Keywords

Citrus; Estrogen receptor; Polymethoxyflavones; Tamoxifen; Ubiquitination.

Figures
Products